Role of resveratrol in prevention and therapy of cancer: Preclinical and clinical studies

Anticancer Research

Volumn 24, Issue 5 A, 2004, Pages 2783-2840

  Aggarwal, Bharat B ^a   Bhardwaj, Anjana ^a   Aggarwal, Rishi S ^a   Seeram, Navindra P ^b   Shishodia, Shishir ^a   Takada, Yasunari ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apoptosis; Cell signaling; Chemoprevention; Invasion; Metastasis; Resveratrol; Review; Transformation; Tumorigenesis

Indexed keywords

2,4,3',5' TETRAMETHOXYSTILBENE; 3,3',4',5,5' PENTAMETHOXYSTILBENE; 3,4' DIMETHOXY 5 HYDROXYSTILBENE; 3,5 DIHYDROXY 4' METHOXYSTILBENE; ALPHA VINFERIN; AMURENSINS I; AMURENSINS L; CYTOKINE; DIDANOSINE; GENE PRODUCT; HEYNEANOL A; HOPEAPHENOL; HYDROXYUREA; ISOHOPEAPHENOL; PICEATANNOL; PROTEIN BCL 2; PROTEIN BCL XL; RESVERATROL; RESVERATROL DERIVATIVE; RHAPONTIGENIN; RHAPONTIN; STILBENE; STILBENE DERIVATIVE; TRANSCRIPTION FACTOR; TRIMETHYLRESVERATROL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITISIFURAN A; VITISIN A; ZALCITABINE; ZIDOVUDINE;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; B CELL LYMPHOMA; BREAST CANCER; CANCER INHIBITION; CANCER PREVENTION; CELL PROLIFERATION; CLINICAL TRIAL; COLON CANCER; DOWN REGULATION; DRUG ISOLATION; DRUG POTENTIATION; DRUG STRUCTURE; GENE ACTIVATION; GENE CONTROL; GROWTH INHIBITION; HEAD CANCER; HEART PROTECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHATIC LEUKEMIA; MELANOMA; MITOSIS INHIBITION; MULTIPLE MYELOMA; MYELOID LEUKEMIA; NECK CANCER; NONHUMAN; OVARY CARCINOMA; PANCREAS CANCER; PLANT ROOT; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; STRUCTURE ACTIVITY RELATION; T CELL LYMPHOMA; THYROID CANCER; UPREGULATION; UTERINE CERVIX CANCER; VERATRUM;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CLINICAL TRIALS; HUMANS; NEOPLASMS; STILBENES; VERATRUM;

EID: 6944250259     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (370)

1. Paul B, Masih I, Deopujari J and Charpentier C: Occurrence of resveratrol and pterostilbene in age-old darakchasava, an ayurvedic medicine from India. J Ethnopharmacol 68: 71-76, 1999.
2. Hain R, Reif HJ, Krause E, Langebartels R, Kindl H, Vornam B, Wiese W, Schmelzer E, Schreier PH, Stocker RH et al: Disease resistance results from foreign phytoalexin expression in a novel plant. Nature 361: 153-156, 1993.
3. Takaoka MJ: J Faculty Sci Hokkaido Imperial U 3: 1-16, 1940.
4. Vastano BC, Chen Y, Zhu N, Ho CT, Zhou Z and Rosen RT: Isolation and identification of stilbenes in two varieties of Polygonum cuspidatum. J Agric Food Chem 48: 253-256, 2000.
5. Lee SK, Mbwambo ZH, Chung H, Luyengi L, Gamez EJ, Mehta RG, Kinghorn AD and Pezzuto JM: Evaluation of the antioxidant potential of natural products. Comb Chem High Throughput Screen 1: 35-46, 1998.
6. Cichewicz RH and Kouzi SA: Resveratrol oligomers: structure, chemistry, and biological activity. J Nat Prod Chem 26: 507-579, 2002.
7. Langcake P and Pryce RJ: The production of resveratrol by Vitis vinifera and other members of the Vitaseae as a response to infection or injury. Physiol Plant Pathol 9: 77-86, 1976.
8. Langcake P and McCarthy W: The relationship of resveratrol production to infection of grapevine leaves by Botrytis cinerea. Vitis 18: 244-253, 1979.
9. Creasy LL and Coffee M: Phytoalexin production potential of grape berries. J Am Soc Hort Sci 113: 230-234, 1988.
10. Kopp P: Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the 'French paradox'? Eur J Endocrinol 138: 619-620, 1998.
11. Sun AY, Simonyi A and Sun GY: The "French Paradox" and beyond: neuroprotective effects of polyphenols. Free Radic Biol Med 32: 314-318, 2002.
12. Hung LM, Chen JK, Huang SS, Lee RS and Su MJ: Cardioprotective effect of resveratrol, a natural antioxidant derived from grapes. Cardiovasc Res 47: 549-555, 2000.
13. Bhat KPL, Kosmeder JW 2nd and Pezzuto JM: Biological effects of resveratrol. Antioxid Redox Signal 3: 1041-1064, 2001.
14. Heredia A, Davis C and Redfield R: Synergistic inhibition of HIV-1 in activated and resting peripheral blood mononuclear cells, monocyte-derived macrophages, and selected drug-resistant isolates with nucleoside analogues combined with a natural product, resveratrol. J Acq Immune Def Synd 25: 246-255, 2000.
15. Docherty JJ, Fu MM, Stiffler BS, Limperos RJ, Pokabla CM and DeLucia AL: Resveratrol inhibition of herpes simplex virus replication. Antiviral Res 43: 145-155, 1999.
16. Docherty JJ, Smith JS, Fu MM, Stoner T and Booth T: Effect of topically applied resveratrol on cutaneous herpes simplex virus infections in hairless mice. Antiviral Res 61: 19-26, 2004.
17. Chan MM: Antimicrobial effect of resveratrol on dermatophytes and bacterial pathogens of the skin. Biochem Pharmacol 63: 99-104, 2002.
18. Daroch F, Hoeneisen M, Gonzalez CL, Kawaguchi F, Salgado F, Solar H and Garcia A: In vitro antibacterial activity of Chilean red wines against Helicobacter pylori. Microbios 104: 79-85, 2001.
19. Mahady GB, Pendland SL and Chadwick LR: Resveratrol and red wine extracts inhibit the growth of CagA+ strains of Helicobacter pylori in vitro. Am J Gastroenterol 98: 1440-1441, 2003.
20. Mahady GB and Pendland SL: Resveratrol inhibits the growth of Helicobacter pylori in vitro. Am J Gastroenterol 95: 1849, 2000.
21. Gusman J, Malonne H and Atassi G: A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis 22: 1111-1117, 2001.
22. Bhat KP and Pezzuto JM: Cancer chemopreventive activity of resveratrol. Ann NY Acad Sci 957: 210-229, 2002.
23. Fremont L: Biological effects of resveratrol. Life Sci 66: 663-673, 2000.
24. Soleas GJ, Diamandis EP and Goldberg DM: Resveratrol: a molecule whose time has come? And gone? Clin Biochem 30: 91-113, 1997.
25. Yang CS, Landau JM, Huang MT and Newmark HL: Inhibition of Carcinogenesis by dietary polyphenolic compounds. Ann Rev Nutr 21: 381-406, 2001.
26. Soleas GJ, Diamandis EP and Goldberg DM: The world of resveratrol. Adv Exp Med Biol 492: 159-182, 2001.
27. Sovak M: Grape extract, resveratrol and its analogs'. A review. J Med Food 4: 93-105, 2001.
28. Pervaiz S: Resveratrol: from grapevines to mammalian biology. Faseb J 17: 1975-1985, 2003.
29. Celotti E, Ferrarini R, Zironi R and Conte LS: Resveratrol content of some wines obtained from dried Valpolicella grapes: Recioto and Amarone. J Chromatogr A 730: 47-52, 1996.
30. Chen RS, Wu PL and Chiou RY: Peanut roots as a source of resveratrol. J Agric Food Chem 50: 1665-1667, 2002.
31. Sobolev VS and Cole RJ: trans-Resveratrol content in commercial peanuts and peanut products. J Agric Food Chem 47: 1435-1439, 1999.
32. Burns J, Yokota T, Ashihara H, Lean ME and Crozier A: Plant foods and herbal sources of resveratrol. J Agric Food Chem 50: 3337-3340, 2002.
33. Lyons MM, Yu C, Toma RB, Cho SY, Reiboldt W, Lee J and van Breemen RB: Resveratrol in raw and baked blueberries and bilberries. J Agric Food Chem 51: 5867-5870, 2003.
34. Powell RG, TePaske MR, Plattner RD, White JE and Clement SL: Isolation of resveratrol from Festuca versuta and evidence for the widespread occurrence of this stilbene in the Poaseae. Phytochemistry 35: 335-338, 1994.
35. Aaviskar A, Haga M, Kuzina K, Puessa T, Raal A and Tsoupras G: Hydroxystilbenes in the roots of Rheum rhaponticum. Proc Estonian Acad Sci 52: 99-107, 2003.
36. Ali Z, Tanaka T, Iliya I, Iinuma M, Furusawa M, Ito T, Nakaya K, Murata J and Darnaedi D: Phenolic constituents of Gnetum klossii. J Nat Prod 66: 558-560, 2003.
37. Kumar RG, Jyostna D, Krupadanam GL and Srimannarayana G: Phenanthrene and stilbenes from pterobolium hexapetallum. Phytochemistry 27: 3625-3626, 2004.
38. Deshpande VH, Srinivasan R and Rao AV: Wood phenolics of Morus species. IV. Phenolics of the heartwood of five Morus species. Indian J Chem 13: 453-457, 1975.
39. Adesanya SA, Ogundana SK and Roberts MF: Dihydrostilbene phytoalexins from Dioscorea bulbifera and D. dumentorum. Phytochemistry 28: 773-774, 1989.
40. Ferrigni NR, McLaughlin JL, Powell RG and Smith CR Jr: Use of potato disc and brine shrimp bioassays to detect activity and isolate piceatannol as the antileukemic principle from the seeds of Euphorbia lagascae. J Nat Prod 47: 347-352, 1984.
41. Tsuruga T, Chun YT, Ebizuka Y and Sankawa U: Biologically active constituents of Melaleuca leucadendron: inhibitors of induced histamine release from rat mast cells. Chem Pharm Bull (Tokyo) 39: 3276-3278, 1991.
42. Inamori Y, Kato Y, Kubo M, Yasuda M, Baba K and Kozawa M: Physiological activities of 3,3′,4,5′-tetrahydroxystubene isolated from the heartwood of Cassia garrettiana CRAIB. Chem Pharm Bull (Tokyo) 32: 213-218, 1984.
43. Ko SK, Lee SM and Whang WK: Anti-platelet aggregation activity of stilbene derivatives from Rheum undulatum. Arch Pharm Res 22: 401-403, 1999.
44. Teguo PW, Decendit S, Krisa S, Deffieux G, Vercauteren J and Merillon JM: The accumulation of stilbene glycosides in Vitis vinifera cell suspension cultures. J Nat Prod 59: 1189-1191, 2001.
45. Rao VSS and Rajaduri S: Isolation of 3,4,3,5- tetrahydroxystilbene(piceatannol) from Cassia marginata heartwood. Aust J Chem 27: 1921-1922, 1968.
46. Zaman A, Prakash S, Wizarat K, Joshi BS, Gawad DH and Likhate MA: Isolation and structure of gnetol, a novel stilbene from Gnetum ula. Indian J Chem 225: 101-104, 1983.
47. Ohguchi K, Tanaka T, Iliya I, Ito T, Iinuma M, Matsumoto K, Akao Y and Nozawa Y: Gnetol as a potent tyrosinase inhibitor from genus Gnetum. Biosci Biotechnol Biochem 67: 663-665, 2003.
48. Djapic N, Djarmati Z, Filip S and Jankov RM: A stilbene from the heartwood of Maclura pomifera. J Serb Chem Soc 68: 235-237, 2003.
49. Hakim EH, Ulinnuha UZ, Syah YM and Ghisalberti EL: Artoindonesianins N and O, new prenylated stilbene and prenylated arylbenzofuran derivatives from Artocarpus gomezianus. Fitoterapia 73: 597-603, 2002.
50. Kanchanapoom T, Suga K, Kasai R, Yamasaki K, Kamel MS, and Mohamed MH: Stilbene and 2-arylbenzofuran glucosides from the rhizomes of Schoenocaulon officinale. Chem Pharm Bull (Tokyo) 50: 863-865, 2002.
51. Lu J, Ho CH, Ghai G and Chen KY: Resveratrol analog, 3,4,5,4′- tetrahydroxystilbene, differentially induces proapoptotic p53/Bax gene expression and inhibits the growth of transformed cells but not their normal counterparts. Carcinogenesis 22: 321-328, 2001.
52. Hathway DE: The use of hydroxystilbene compounds as taxonomic tracers in the genus Eucalyptus. Biochem J 83: 80-84, 1962.
53. King FE, King TJ, Godson DH and Manning LC: Chemistry of extractives from hardwoods. XXVII. The occurrence of 3,3′,4,5′-tetrahydroxy and 3,3′,4,5,5′-pentahydroxystilbene in Vouacapoua species. J Chem Soc 4477-4480, 1956.
54. Yao CS, Lin M, Liu X and Wang YH: Stilbenes from Gnetum cleistostachyum. HuaXue Xuebao 61: 1331-1334, 2003.
55. Sofronova VE, Petrov KA, Sofronova V, Kriolitozony E, Petrov KA and Yalutsk R: New phenolic growth inhibitor from buds of Duschekia fruticosa (Rupr). Pouzar Rastitel'nye Resursy 38: 92-97, 2002.
56. Ali MA and Debnath DC: Isolation and characterization of antbacterial constituent from devdaru (lignum of Polyalthis longifolia L.). Bang J Sci Ind Res 32: 20-24, 1997.
57. Ngo KS and Brown GD: Stilbenes, monoterpenes, diarylheptanoids, labdanes and chalcones from Alpinia katsumadai. Phytochemistry 47: 1117-1123, 1998.
58. Kuroyanagi M, Yamamoto Y, KFukushima S, Ueno A, Noro T and Miyase T: Chemical studies on the constituents of Polygonum nodosum. Chem Pharm Bull (Tokyo) 30: 1620-1628, 1982.
59. Rudloff E and Jorgensen E: Biosynthesis of pinosylvin in the sapwood of Pinus resinosa. Phytochemistry 2: 297-304, 1963.
60. Takasugi M, Kawshima S, Monde K, Katsui N, Masamune T and Shirata A: Antifungal compounds from Dioscorea batatas inoculated with Pseudomonas cichorü. Phytochemistry 26: 371-375, 1987.
61. Lu M, Cai YJ, Fang JG, Zhou YL, Liu ZL and Wu LM: Efficiency and structure-activity relationship of the antioxidant action of resveratrol and its analogs. Pharmazie 57: 474-478, 2002.
62. Cai YJ, Fang JG, Ma LP, Yang L and Liu ZL: Inhibition of free radical-induced peroxidation of rat liver microsomes by resveratrol and its analogues. Biochim Biophys Acta 1637: 31-38, 2003.
63. Matsuoka A, Takeshita K, Furuta A, Ozaki M, Fukuhara K and Miyata N: The 4′-hydroxy group is responsible for the in vitro cytogenetic activity of resveratrol. Mutat Res 521: 29-35, 2002.
64. Thakkar K, Geahlen RL and Cushman M: Synthesis and protein-tyrosine kinase inhibitory activity of polyhydroxylated stilbene analogues of piceatannol. J Med Chem 36: 2950-2955, 1993.
65. Fang JG, Lu M, Chen ZH, Zhu HH, Li Y, Yang L, Wu LM, and Liu ZL: Antioxidant effects of resveratrol and its analogues against the free-radical-induced peroxidation of linoleic acid in micelles. Chemistry 8: 4191-4198, 2002.
66. Lu M, Fang JG, Liu ZL and Wu LM: Effects of resveratrol and its analogs on scavenging hydroxyl radicals: evaluation of EPR spin trapping method. App Mag Res 22: 475-481, 2002.
67. Eddarir S, Zouanante A and Rolando C: Fluorinated resveratrol and pterostilbene. Tett Lett 42: 9127-9130, 2001.
68. Lee HJ, Seo JW, Lee BH, Chung KH and Chi DY: Syntheses and radical scavenging activities of resveratrol derivatives. Bioorg Med Chem Lett 14: 463-466, 2004.
69. Matsuda H, Tomohiro N, Hiraba K, Harima S, Ko S, Matsuo K, Yoshikawa M and Kubo M: Study on anti-Oketsu activity of rhubarb II. Anti-allergic effects of stilbene components from Rhei undulali Rhizoma (dried rhizome of Rheum undulatum cultivated in Korea). Biol Pharm Bull 24: 264-267, 2001.
70. Bangani V, Crouch R and Mulholland DA: Homoisoflavanones and stilbenoids from Scilla nervosa. Phytochemistry 51: 947-951, 1999.
71. Wang QL, Lin M and Liu GT: Antioxidative activity of natural isorhapontigenin. Jpn J Pharmacol 87: 61-66, 2001.
72. Feng Y, Bing W, Lin Z and Zhi ZZ: Synthesis of the natural products resveratrol and isorhapotogenin (isorhapotigenin). Chin Chem Lett 9: 1003-1004, 1998.
73. Chun YJ, Ryu SY, Jeong TC and Kim MY: Mechanism-based inhibition of human cytochrome P450 1A1 by rhapontigenin. Drug Metab Dispos 29: 389-393, 2001.
74. Gonzalez MJTG, Pinto MMM, Kijjoa A, Anantachoke C and Herz W: Stilbenes and other constituents of Knema austrosiamensis. Phytochemistry 32: 433-438, 1993.
75. Kerem Z, Regev-Shoshani G, Flaishman MA and Sivan L: Resveratrol and two monomethylated Stilbenes from Israeli Rumex bucephalophoms and their antioxidant potential. J Nat Prod 66: 1270-1272, 2003.
76. Roberti M, Pizzirani D, Simoni D, Rondanin R, Baruchello R, Bonora C, Buscemi F, Grimaudo S and Tolomeo M: Synthesis and biological evaluation of resveratrol and analogues as apoptosis-inducing agents. J Med Chem 46: 3546-3554, 2003.
77. Kim YM, Yun J, Lee CK, Lee H, Min KR and Kim Y: Oxyresveratrol and hydroxystilbene compounds. Inhibitory effect on tyrosinase and mechanism of action. J Biol Chem 277: 16340-16344, 2002.
78. Hu Y, King Z and Liu D: Determination of pterostilbene in Dragon's Blood by RP-HPLC. Yaowu Fenxi Zazhi 22: 428-430, 2002.
79. Rimando AM, Cuendet M, Desmarchelier C, Mehta RG, Pezzuto JM and Duke SO: Cancer chemopreventive and antioxidant activities of pterostilbene, a naturally occurring analogue of resveratrol. J Agric Food Chem 50: 3453-3457, 2002.
80. Bhakuni DS and Chaturvedi R: Chemical constituents of Crotalaria madurensis. J Nat Prod 47: 585-591, 1984.
81. Torres P, Avila JG, Romo de Vivar A, Garcia AM, Marin JC, Aranda E and Cespedes CL: Antioxidant and insect growth regulatory activities of stilbenes and extracts from Yucca periculosa. Phytochemistry 64: 463-473, 2003.
82. Olas B, Wachowicz B, Stochmal A and Oleszek W: Inhibition of oxidative stress in blood platelets by different phenolics from Yucca schidigera Roezl. bark. Nutrition 19: 633-640, 2003.
83. Messana I, Ferrari F, Cavalcanti MS and Morace G: An anthraquinone and three naphthopyrone derivatives from Cassia pudibunda. Phytochemistry 30: 708-710,1991.
84. Juliawaty LD, Kitajima M, Takayama H, Achmad SA and Aimi N: A new type of stilbene-related secondary metabolite, idenburgene, from Cryptocarya idenburgensis. Chem Pharm Bull (Tokyo) 48: 1726-1728, 2000.
85. Likhitwitayawuid K, Sawasdee K and Kirtikara K: Flavonoids and stilbenoids with COX-1 and COX-2 inhibitory activity from Dracaena loureiri. Planta Med 68: 841-843, 2002.
86. Hu Y, Tu P, Li R, Wan Z and Wang D: Studies of stilbene derivatives from Dracaena cochinchinensis and their antifungal activities. Zhonfcaoyao 32: 104-106, 2001.
87. Aritomi M and A., DDM 15. 2006-8, 1976.
88. Duenas M, Hernandez T and Estrella I: Phenolic composition of the cotyledon and the seed coat of lentils (Lens culinaris L.). Eur Food Res Tech 57: 478-483, 2002.
89. Song HK, Jung J, Park KH and Lim Y: Leukotriene D4 antagonistic acivity of a stilbene derivative isolated from the bark of Pinus koraiensis. Argric Chem Biotech 44: 199-201, 2001.
90. Teguo PW, Fauconneau B, Deffieux G, Huguet F, Vercauteren J and Merillon JM: Isolation, identification, and antioxidant activity of three stilbene glucosides newly extracted from Vitis vinifera cell cultures. J Nat Prod 61: 655-657, 1998.
91. Lee JP, Min BS, An RB, Na MK, Lee SM, Lee HK, Kim JG, Bae KH and Kang SS: Stilbenes from the roots of Pleuropterus ciliinervis and their antioxidant activities. Phytochemistry 64: 759-763, 2003.
92. Kageura T, Matsuda H, Morikawa T, Toguchida I, Harima S, Oda M and Yoshikawa M: Inhibitors from rhubarb on lipopolysaccharide-induced nitric oxide production in macrophages: structural requirements of stilbenes for the activity. Bioorg Med Chem 9: 1887-1893, 2001.
93. Kashiwada Y, Nonaka G, Nishioka I, Nishizawa M and Yamagishi T: Studies on rhubarb (Rhei rhizoma) XIV. Isolation and characterization of stilbene glucosides from Chinese rhubarb. Chem Pharm Bull (Tokyo) 36: 1545-1549, 1988.
94. Decendit A, Waffo-Teguo P, Richard T, Krisa S, Vercauteren J, Monti JP, Deffieux G and Merillon JM: Galloylated catechins and stilbene diglucosides in Vitis vinifera cell suspension cultures. Phytochemistry 60: 795-798, 2002.
95. Orsini F, Pelizzoni F, Bellini B and Miglierini G: Synthesis of biologically active polyphenolic glycosides (combretastatin and resveratrol series). Carbohydr Res 301: 95-109, 1997.
96. Wanjala CC and Majinda RR: A new stilbene glycoside from Elephantorrhiza goetzei. Fitoterapia 72: 649-655, 2001.
97. Hano Y, Goi K, Nomura T and Ueda S: Sequential glucosylation determined by NMR in the biosynthesis of mulberroside D, a cis-oxyresveratrol diglucoside, in Morus alba cell cultures. Life Sci 53: 237-241, 1997.
98. Hirakura K, Fujimoto Y, Fukai T and Nomura T: Constituents of the cultivated mulberry tree. Two phenolic glycosides from the root bark of the cultivated melberry tree (Murus lhou). J Nat Prod 49: 218-224, 1986.
99. Iliya I, Tanaka T, Iinuma M, Furusawa M, Ali Z, Nakaya K, Murata J and Darnaedi D: Five stilbene glucosides from Gnetum gnemonoides and Gnetum africanum. Helv Chem Acta 85: 2394-2402, 2002.
100. Iliya I, Ali Z, Tanaka T, Iinuma M, Furusawa M, Nakaya K, Murata J, Darnaedi D, Matsuura N and Ubukata M: Stilbene derivatives from Gnetum gnemon Linn. Phytochemistry 62: 601-606, 2003.
101. Askari A, Worthen LR and Shimizu Y: Gaylussacin, a new stilbene derivative from species of Gaylussacia. Lloydia 35: 49-54, 1972.
102. Ito T, Ibrahim I, Tanaka T, Nakaya K, Iinuma M, Takahashi Y, Naganawa H, Akao Y, Nozawa Y, Ohyama M, Nakanishi Y, Bastow KF and Lee KH: Chemical constituents of dipterocarpaceaeous and gnetaceaeous plants and their biological activities. Tennen Yuki Kago Toron Koen Yosh 43: 449-454, 2001.
103. Sotheeswaran S and Pasupathy V: Distribution of resveratrol oligomers in plants. Phytochemistry 32: 1083-1092, 1993.
104. Hernandez-Romero,Y, Rojas JI, Castillo R, Rojas A and Mata R: Spasmolytic effects, mode of action, and structure-activity relationships of stilbenoids from Nidema boothii. J Nat Prod 67: 160-167, 2004.
105. Trela B and Waterhouse A: Resveratrol: isomeric molar absorptivities and stability. J Agric Food Chem 44: 1253-1257, 1996.
106. Deak M and Falk H: On the chemistry of resveratrol diastereomers. Monat fur Chem 134: 883-888, 2003.
107. Siemann EH and Creasy LL: Concentration of the phytoalexin resveratrol in wine. An J Eno Vitic 43: 49-52, 1992.
108. Cao H, Pan X, Li C, Zhou C, Deng F and Li T: Density functional theory calculations for resveratrol. Bioorg Med Chem Lett 13: 1869-1871, 2003.
109. Ohguchi K, Tanaka T, Kido T, Baba K, Iinuma M, Matsumoto K, Akao Y and Nozawa Y: Effects of hydroxystilbene derivatives on tyrosinase activity. Biochem Biophys Res Commun 307: 861-863, 2003.
110. Stivala LA, Savio M, Carafoli F, Perucca P, Bianchi L, Maga G, Forti L, Pagnoni UM, Albini A, Prosperi E and Vannini V: Specific structural determinants are responsible for the antioxidant activity and the cell cycle effects of resveratrol. J Biol Chem 276: 22586-22594, 2001.
111. Ashikawa K, Majumdar S, Banerjee S, Bharti AC, Shishodia S and Aggarwal BB: Piceatannol inhibits TNF-induced NF-kappaB activation and NF-kappaB-mediated gene expression through suppression of IkappaBalpha kinase and p65 phosphorylation. J Immunol 769: 6490-6497, 2002.
112. Billard C, Izard JC, Roman V, Kern C, Mathiot C, Mentz F and Kolb JP: Comparative antiproliferative and apoptotic effects of resveratrol, epsilon-viniferin and vine-shots derived polyphenols (vineatrols) on chronic B lymphocytic leukemia cells and normal human lymphocytes. Leuk Lymphoma 43: 1991-2002, 2002.
113. Roman V, Billard C, Kern C, Ferry-Dumazet H, Izard JC, Mohammad R, Mossalayi DM and Kolb JP: Analysis of resveratrol-induced apoptosis in human B-cell chronic leukaemia. Br J Haematol 117: 842-851, 2002.
114. Dorrie J, Gerauer H, Wachter Y and Zunino SJ: Resveratrol induces extensive apoptosis by depolarizing mitochondrial membranes and activating caspase-9 in acute lymphoblastic leukemia cells. Cancer Res 61: 4731-4739, 2001.
115. Wieder T, Prokop A, Bagci B, Essmann F, Bernicke D, Schulze-Osthoff K, Dorken B, Schmalz HG, Daniel PT and Henze G: Piceatannol, a hydroxylated analog of the chemopreventive agent resveratrol, is a potent inducer of apoptosis in the lymphoma cell line BJAB and in primary, leukemic lymphoblasts. Leukemia 15: 1735-1742, 2001.
116. Hayashibara T, Yamada Y, Nakayama S, Harasawa H, Tsuruda K, Sugahara K, Miyanishi T, Kamihira S, Tomonaga M and Maita T: Resveratrol induces downregulation in survivin expression and apoptosis in HTLV-1-infected cell lines: a prospective agent for adult T cell leukemia chemotherapy. Nutr Cancer 44: 193-201, 2002.
117. Tinhofer I, Bernhard D, Senfter M, Anether G, Loeffler M, Kroemer G, Kofler R, Csordas A and Greil R: Resveratrol, a tumor-suppressive compound from grapes, induces apoptosis via a novel mitochondrial pathway controlled by Bcl-2. Faseb J 15: 1613-1615, 2001.
118. Clement MV, Hirpara JL, Chawdhury SH and Pervaiz S: Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells. Blood 92: 996-1002, 1998.
119. Tsan MF, White JE, Maheshwari JG, Bremner TA and Sacco J: Resveratrol induces Fas signalling-independent apoptosis in THP-1 human monocytic leukaemia cells. Br J Haematol 109: 405-412, 2000.
120. Surh YJ, Hurh YJ, Kang JY, Lee E, Kong G and Lee SJ: Resveratrol, an antioxidant present in red wine, induces apoptosis in human promyelocytic leukemia (HL-60) cells. Cancer Lett 140: 1-10, 1999.
121. Park JW, Choi YJ, Suh SI, Baek WK, Suh MH, Jin IN, Min DS, Woo JH, Chang JS, Passaniti A, Lee YH and Kwon TK: Bcl-2 overexpression attenuates resveratrol-induced apoptosis in U937 cells by inhibition of caspase-3 activity. Carcinogenesis 22: 1633-1639, 2001.
122. Estrov Z, Shishodia S, Faderl S, Harris D, Van Q, Kantarjian HM, Talpaz M and Aggarwal BB: Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. Blood 702: 987-995, 2003.
123. Lee SH, Ryu SY, Kim HB, Kim MY and Chun YJ: Induction of apoptosis by 3,4′-dimethoxy-5-hydroxystilbene in human promyeloid leukemic HL-60 cells. Planta Med 68: 123-127, 2002.
124. Kang JH, Park YH, Choi SW, Yang EK and Lee WJ: Resveratrol derivatives potently induce apoptosis in human promyelocytic leukemia cells. Exp Mol Med 35: 467-474; 2003.
125. Pendurthi UR and Rao LV: Resveratrol suppresses agonist-induced monocyte adhesion to cultured human endothelial cells. Thromb Res 106: 243-248, 2002.
126. Gao X, Xu YX, Janakiraman N, Chapman RA and Gautam SC: Immunomodulatory activity of resveratrol: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production. Biochem Pharmacol 62: 1299-1308, 2001.
127. Stewart JR, Christman KL and O'Brian CA: Effects of resveratrol on the autophosphorylation of phorbol ester-responsive protein kinases: inhibition of protein kinase D but not protein kinase C isozyme autophosphorylation. Biochem Pharmacol 60: 1355-1359, 2000.
128. Mgbonyebi OP, Russo J and Russo IH: Antiproliferative effect of synthetic resveratrol on human breast epithelial cells. Int J Oncol 12: 865-869, 1998.
129. Serrero G and Lu R: Effect of resveratrol on the expression of autocrine growth modulators in human breast cancer cells. Antioxid Redox Signal 3: 969-979, 2001.
130. Nakagawa H, Kiyozuka Y, Uemura Y, Senzaki H, Shikata N, Hioki K and Tsubura A: Resveratrol inhibits human breast cancer cell growth and may mitigate the effect of linoleic acid, a potent breast cancer cell stimulator. J Cancer Res Clin Oncol 127: 258-264, 2001.
131. Pozo-Guisado E, Alvarez-Barrientos A, Mulero-Navarro S, Santiago-Josefat B and Fernandez-Salguero PM: The antiproliferative activity of resveratrol results in apoptosis in MCF-7 but not in MDA-MB-231 human breast cancer cells: cell-specific alteration of the cell cycle. Biochem Pharmacol 64: 1375-1386, 2002.
132. Lu R and Serrero G: Resveratrol, a natural product derived from grape, exhibits antiestrogenic activity and inhibits the growth of human breast cancer cells. J Cell Physiol 179: 297-304, 1999.
133. Bove K, Lincoln DW and Tsan MF: Effect of resveratrol on growth of 4T1 breast cancer cells in vitro and in vivo. Biochem Biophys Res Commun 297: 1001-1005, 2002.
134. Damianaki A, Bakogeorgou E, Kampa M, Notas G, Hatzoglou A, Panagiotou S, Gemetzi C, Kouroumalis E, Martin PM and Castanas E: Potent inhibitory action of red wine polyphenols on human breast cancer cells. J Cell Biochem 78: 429-441, 2000.
135. Hsieh TC, Burfeind P, Laud K, Backer JM, Traganos F, Darzynkiewicz Z and Wu JM: Cell cycle effects and control of gene expression by resveratrol in human breast carcinoma cell lines with different metastatic potentials. Int J Oncol 15: 245-252, 1999.
136. Kim YA, Choi BT, Lee YT, Park DI, Rhee SH, Park KY and Choi YH: Resveratrol inhibits cell proliferation and induces apoptosis of human breast carcinoma MCF-7 cells. Oncol Rep 11: 441-446, 2004.
137. Scarlatti F, Sala G, Somenzi G, Signorelli P, Sacchi N and Ghidoni R: Resveratrol induces growth inhibition and apoptosis in metastatic breast cancer cells via de novo ceramide signaling. Faseb J 17: 2339-2341, 2003.
138. El-Mowafy AM and Alkhalaf M: Resveratrol activates adenylyl-cyclase in human breast cancer cells: a novel, estrogen receptor-independent cytostatic mechanism. Carcinogenesis 24: 869-873, 2003.
139. Stewart JR, Ward NE, Ioannides CG and O'Brian CA: Resveratrol preferentially inhibits protein kinase C-catalyzed phosphorylation of a cofactor-independent, arginine-rich protein substrate by a novel mechanism. Biochemistry 38: 13244-13251, 1999.
140. Lee JE and Safe S: Involvement of a post-transcriptional mechanism in the inhibition of CYP1A1 expression by resveratrol in breast cancer cells. Biochem Pharmacol 62: 1113-1124, 2001.
141. Subbaramaiah K, Chung WJ, Michaluart P, Telang N, Tanabe T, Inoue H, Jang M, Pezzuto JM and Dannenberg AJ: Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J Biol Chem 273: 21875-21882, 1998.
142. Subbaramaiah K and Dannenberg AJ: Resveratrol inhibits the expression of cyclooxygenase-2 in mammary epithelial cells. Adv Exp Med Biol 492: 147-157, 2001.
143. Mahyar-Roemer M, Katsen A, Mestres P and Roemer K: Resveratrol induces colon tumor cell apoptosis independently of p53 and precede by epithelial differentiation, mitochondrial proliferation and membrane potential collapse. Int J Cancer 94: 615-622, 2001.
144. Wolter F and Stein J: Resveratrol enhances the differentiation induced by butyrate in caco-2 colon cancer cells. J Nutr 132: 2082-2086, 2002.
145. Wolter F, Akoglu B, Clausnitzer A and Stein J: Downregulation of the cyclin D1/Cdk4 complex occurs during resveratrol-induced cell cycle arrest in colon cancer cell lines. J Nutr 131: 2197-2203, 2001.
146. Delmas D, Rebe C, Lacour S, Filomenko R, Athias A, Gambert P, Cherkaoui-Malki M, Jannin B, Dubrez-Daloz L, Latruffe N and Solary E: Resveratrol-induced apoptosis is associated with Fas redistribution in the rafts and the formation of a death-inducing signaling complex in colon cancer cells. J Biol Chem 278: 41482-41490, 2003.
147. Liang YC, Tsai SH, Chen L, Lin-Shiau SY and Lin JK: Resveratrol-induced G2 arrest through the inhibition of CDK7 and p34CDC2 kinases in colon carcinoma HT29 cells. Biochem Pharmacol 65: 1053-1060, 2003.
148. Nam KA, Kim S, Heo YH and Lee SK: Resveratrol analog, 3,5,2′,4′-tetramethoxy-trans-stilbene, potentiates the inhibition of cell growth and induces apoptosis in human cancer cells. Arch Pharm Res 24: 441-445, 2001.
149. Tessitore L, Davit A, Sarotto I and Caderni G: Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21(CIP) expression. Carcinogenesis 21: 1619-1622, 2000.
150. Ito T, Akao Y, Tanaka T, Iinuma M and Nozawa Y: Vaticanol C, a novel resveratrol tetramer, inhibits cell growth through induction of apoptosis in colon cancer cell lines. Biol Pharm Bull 25: 147-148, 2002.
151. Wolter F, Clausnitzer A, Akoglu B and Stein J: Piceatannol, a natural analog of resveratrol, inhibits progression through the S phase of the cell cycle in colorectal cancer cell lines. J Nutr 132: 298-302, 2002.
152. Ding XZ and Adrian TE: Resveratrol inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Pancreas 25: e71-76, 2002.
153. Atten MJ, Attar BM, Milson T and Holian O: Resveratrol-induced inactivation of human gastric adenocarcinoma cells through a protein kinase C-mediated mechanism. Biochem Pharmacol 62: 1423-1432, 2001.
154. Holian O, Wahid S, Atten MJ and Attar BM: Inhibition of gastric cancer cell proliferation by resveratrol: role of nitric oxide. Am J Physiol Gastrointest Liver Physiol 282: G809-816, 2002.
155. Zhou HB, Yan Y, Sun YN and Zhu JR: Resveratrol induces apoptosis in human esophageal carcinoma cells. World J Gastroenterol 9: 408-411, 2003.
156. Hsieh TC and Wu JM: Grape-derived chemopreventive agent resveratrol decreases prostate-specific antigen (PSA) expression in LNCaP cells by an androgen receptor (AR)-independent mechanism. Anticancer Res 20: 225-228, 2000.
157. Hsieh TC and Wu JM: Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell lines. Exp Cell Res 249: 109-115, 1999.
158. Lin HY, Shih A, Davis FB, Tang HY, Martino LJ, Bennett JA and Davis PJ: Resveratrol induced serine phosphorylation of p53 causes apoptosis in a mutant p53 prostate cancer cell line. J Urol 168: 748-755, 2002.
159. Mitchell SH, Zhu W and Young CY: Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Res 59: 5892-5895, 1999.
160. Kampa M, Hatzoglou A, Notas G, Damianaki A, Bakogeorgou E, Gemetzi C, Kouroumalis E, Martin PM and Castanas E: Wine antioxidant polyphenols inhibit the proliferation of human prostate cancer cell lines. Nutr Cancer 37: 223-233, 2000.
161. Kuwajerwala N, Cifuentes E, Gautam S, Menon M, Barrack ER and Reddy GP: Resveratrol induces prostate cancer cell entry into s phase and inhibits DNA synthesis. Cancer Res 62: 2488-2492, 2002.
162. Narayanan BA, Narayanan NK, Re GG and Nixon DW: Differential expression of genes induced by resveratrol in LNCaP cells: p53-mediated molecular targets. Int J Cancer 104: 204-212, 2003.
163. Stewart JR and O'Brian CA: Resveratrol antagonizes EGFR-dependent Erk1/2 activation in human androgen-independent prostate cancer cells with associated isozyme-selective PKCalpha inhibition. Invest New Drugs 22: 107-117, 2004.
164. Niles RM, McFarland M, Weimer MB, Redkar A, Fu YM and Meadows GG: Resveratrol is a potent inducer of apoptosis in human melanoma cells. Cancer Lett 190: 157-163, 2003.
165. Ahmad N, Adhami VM, Afaq F, Feyes DK and Mukhtar H: Resveratrol causes WAF-1/p21-mediated G(1)-phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 cells. Clin Cancer Res 7: 1466-1473, 2001.
166. Adhami VM, Afaq F and Ahmad N: Involvement of the retinoblastoma (pRb)-E2F/DP pathway during antiproliferative effects of resveratrol in human epidermoid carcinoma (A431) cells. Biochem Biophys Res Commun 288: 579-585, 2001.
167. Larrosa M, Tomas-Barberan FA and Espin JC: Grape polyphenol resveratrol and the related molecule 4-hydroxystilbene induce growth inhibition, apoptosis, S-phase arrest, and upregulation of cyclins A, E, and B1 in human SK-Mel-28 melanoma cells. J Agric Food Chem 51: 4576-4584, 2003.
168. Kim YA, Lee WH, Choi TH, Rhee SH, Park KY and Choi YH: Involvement of p21WAF1/CIP1, pRB, Bax and NF-kappaB in induction of growth arrest and apoptosis by resveratrol in human lung carcinoma A549 cells. Int J Oncol 23: 1143-1149, 2003.
169. Matsuoka A, Furuta A, Ozaki M, Fukuhara K and Miyata N: Resveratrol, a naturally occurring polyphenol, induces sister chromatid exchanges in a Chinese hamster lung (CHL) cell line. Mutat Res 494: 107-113, 2001.
170. Mollerup S, Ovrebo S and Haugen A: Lung carcinogenesis: resveratrol modulates the expression of genes involved in the metabolism of PAH in human bronchial epithelial cells. Int J Cancer 92: 18-25, 2001.
171. Delmas D, Jannin B, Malki MC and Latruffe N: Inhibitory effect of resveratrol on the proliferation of human and rat hepatic derived cell lines. Oncol Rep 7: 847-852, 2000.
172. Kozuki Y, Miura Y and Yagasaki K: Resveratrol suppresses hepatoma cell invasion independently of its anti-proliferative action. Cancer Lett 167: 151-156, 2001.
173. De Ledinghen V, Monvoisin A, Neaud V, Krisa S, Payrastre B, Bedin C, Desmouliere A, Bioulac-Sage P and Rosenbaum J: Trans-resveratrol, a grapevine-derived polyphenol, blocks hepatocyte growth factor-induced invasion of hepatocellular carcinoma cells. Int J Oncol 19: 83-88, 2001.
174. Bhat KP and Pezzuto JM: Resveratrol exhibits cytostatic and antiestrogenic properties with human endometrial adeno-carcinoma (Ishikawa) cells. Cancer Res 61: 6137-6144, 2001.
175. Shih A, Davis FB, Lin HY and Davis PJ: Resveratrol induces apoptosis in thyroid cancer cell lines via a MAPK- and p53-dependent mechanism. J Clin Endocrinol Metab 87: 1223-1232, 2002.
176. Elattar TM and Virji AS: The effect of red wine and its components on growth and proliferation of human oral squamous carcinoma cells. Anticancer Res 19: 5407-5414, 1999.
177. ElAttar TM and Virji AS: Modulating effect of resveratrol and quercetin on oral cancer cell growth and proliferation. Anticancer Drugs 10: 187-193, 1999.
178. Babich H, Reisbaum AG and Zuckerbraun HL: In vitro response of human gingival epithelial S-G cells to resveratrol. Toxicol Lett 114: 143-153, 2000.
179. Miloso M, Bertelli AA, Nicolini G and Tredici G: Resveratrol-induced activation of the mitogen-activated protein kinases, ERK1 and ERK2, in human neuroblastoma SH-SY5Y cells. Neurosci Lett 264: 141-144, 1999.
180. Nicolini G, Rigolio R, Miloso M, Bertelli AA and Tredici G: Anti-apoptotic effect of trans-resveratrol on paclitaxel-induced apoptosis in the human neuroblastoma SH-SY5Y cell line. Neurosci Lett 302: 41-44, 2001.
181. Jang JH and Surh YJ: Protective effects of resveratrol on hydrogen peroxide-induced apoptosis in rat pheochromocytoma (PC12) cells. Mutat Res 496: 181-190, 2001.
182. Yang SH, Kim JS, Oh TJ, Kim MS, Lee SW, Woo SK, Cho HS, Choi YH, Kim YH, Rha SY, Chung HC and An SW: Genome-scale analysis of resveratrol-induced gene expression profile in human ovarian cancer cells using a cDNA microarray. Int J Oncol 22: 741-750, 2003.
183. Kaneuchi M, Sasaki M, Tanaka Y, Yamamoto R, Sakuragi N and Dahiya R: Resveratrol suppresses growth of Ishikawa cells through down-regulation of EGF. Int J Oncol 23: 1167-1172, 2003.
184. Opipari AW Jr, Tarr L, Boitano AE, Sorenson DR, Aurora A and Liu JR: Resveratrol-induced autophagocytosis in ovarian cancer cells. Cancer Res 64: 696-703, 2004.
185. Bhat KP, Lantvit D, Christov K, Mehta RG, Moon RC and Pezzuto JM: Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer Res 61: 7456-7463, 2001.
186. Zoberi I, Bradbury CM, Curry HA, Bisht KS, Goswami PC, Roti Roti JL and Gius D: Radiosensitizing and anti-proliferative effects of resveratrol in two human cervical tumor cell lines. Cancer Lett 175: 165-173, 2002.
187. Joe AK, Liu H, Suzui M, Vural ME, Xiao D and Weinstein IB: Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines. Clin Cancer Res 8: 893-903, 2002.
188. Zou J, Huang Y, Chen Q, Wang N, Cao K, Hsieh TC and Wu JM: Suppression of mitogenesis and regulation of cell cycle traverse by resveratrol in cultured smooth muscle cells. Int J Oncol 15: 647-651, 1999.
189. Green DR and Reed JC: Mitochondria and apoptosis. Science 281: 1309-1312, 1998.
190. Ito T, Akao Y, Yi H, Ohguchi K, Matsumoto K, Tanaka T, Iinuma M and Nozawa Y: Antitumor effect of resveratrol oligomers against human cancer cell lines and the molecular mechanism of apoptosis induced by vaticanol C. Carcinogenesis 24: 1489-1497, 2003.
191. Bernhard D, Tinhofer I, Tonko M, Hubl H, Ausserlechner MJ, Greil R, Kofler R and Csordas A: Resveratrol causes arrest in the S-phase prior to Fas-independent apoptosis in CEM-C7H2 acute leukemia cells. Cell Death Differ 7: 834-842, 2000.
192. Zheng J and Ramirez VD: Piceatannol, a stilbene phytochemical, inhibits mitochondrial FOF1-ATPase activity by targeting the F1 complex. Biochem Biophys Res Commun 261: 499-503, 1999.
193. Huang C, Ma WY, Goranson A and Dong Z: Resveratrol suppresses cell transformation and induces apoptosis through a p53-dependent pathway. Carcinogenesis 20: 237-242, 1999.
194. Hsieh TC, Juan G, Darzynkiewicz Z and Wu JM: Resveratrol increases nitric oxide synthase, induces accumulation of p53 and p21(WAF1/CIP1), and suppresses cultured bovine pulmonary artery endothelial cell proliferation by perturbing progression through S and G2. Cancer Res 59: 2596-2601, 1999.
195. She QB, Huang C, Zhang Y and Dong Z: Involvement of c-jun NH(2)-terminal kinases in resveratrol-induced activation of p53 and apoptosis. Mol Carcinog 33: 244-250, 2002.
196. She QB, Bode AM, Ma WY, Chen NY and Dong Z: Resveratrol-induced activation of p53 and apoptosis is mediated by extracellular-signal-regulated protein kinases and p38 kinase. Cancer Res 61: 1604-1610, 2001.
197. Haider UG, Sorescu D, Griendling KK, Vollmar AM and Dirsch VM: Resveratrol increases serine 15-phosphorylated but transcriptionally impaired p53 and induces a reversible DNA replication block in serum-activated vascular smooth muscle cells. Mol Pharmacol 63: 925-932, 2003.
198. Baek SJ, Wilson LC and Eling TE: Resveratrol enhances the expression of non-steroidal anti-inflammatory drug-activated gene (NAG-1) by increasing the expression of p53. Carcinogenesis 23: 425-434, 2002.
199. Schneider Y, Chabert P, Stutzmann J, Coelho D, Fougerousse A, Gosse F, Launay JF, Brouillard R and Raul F: Resveratrol analog (Z)-3,5,4′- trimethoxystilbene is a potent anti-mitotic drug inhibiting tubulin polymerization. Int J Cancer 107: 189-196, 2003.
200. Aggarwal BB: Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 3: 745-756, 2003.
201. Manna SK, Mukhopadhyay A and Aggarwal BB: Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol 164: 6509-6519, 2000.
202. Holmes-McNary M and Baldwin AS Jr: Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IkappaB kinase. Cancer Res 60: 3477-3483, 2000.
203. Pellegatta F, Bertelli AA, Staels B, Duhera C, Fulgenzi A and Ferrero ME: Different short- and long-term effects of resveratrol on nuclear factor-kappaB phosphorylation and nuclear appearance in human endothelial cells. Am J Clin Nutr 77: 1220-1228, 2003.
204. Adhami VM, Afaq F and Ahmad N: Suppression of ultraviolet B exposure-mediated activation of NF-kappaB in normal human keratinocytes by resveratrol. Neoplasia 5: 74-82, 2003.
205. Tsai SH, Lin-Shiau SY and Lin JK: Suppression of nitric oxide synthase and the down-regulation of the activation of NFkappaB in macrophages by resveratrol. Br J Pharmacol 126: 673-680, 1999.
206. Bertelli AA: Recent progress in research, on wine and its components and their favorable effects on health. Drugs Exp Clin Res 25: 51-52, 1999.
207. Dong Z: Effects of food factors on signal transduction pathways. Biofactors 12: 17-28, 2000.
208. Cho DI, Koo NY, Chung WJ, Kim TS, Ryu SY, Im SY and Kim KM: Effects of resveratrol-related hydroxystilbenes on the nitric oxide production in macrophage cells: structural requirements and mechanism of action. Life Sci 71: 2071-2082, 2002.
209. Eferl R and Wagner EF: AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 3: 859-868, 2003.
210. Shaulian E and Karin M: AP-1 as a regulator of cell life and death. Nat Cell Biol 4: E131-136, 2002.
211. Shen F, Chen SJ, Dong XJ, Zhong H, Li YT and Cheng GF: Suppression of IL-8 gene transcription by resveratrol in phorbol ester treated human monocytic cells. J Asian Nat Prod Res 5: 151-157, 2003.
212. Subbaramaiah K, Michaluart P, Chung WJ, Tanabe T, Telang N and Dannenberg AJ: Resveratrol inhibits cyclooxygenase-2 transcription in human mammary epithelial cells. Ann NY Acad Sci 889: 214-223, 1999.
213. Yu R, Hebbar V, Kim DW, Mandlekar S, Pezzuto JM and Kong AN: Resveratrol inhibits phorbol ester and UV-induced activator protein 1 activation by interfering with mitogen-activated protein kinase pathways. Mol Pharmacol 60: 217-224, 2001.
214. Wolter F, Turchanowa L and Stein J: Resveratrol-induced modification of polyamine metabolism is accompanied by induction of c-Fos. Carcinogenesis 24: 469-474, 2003.
215. Ragione FD, Cucciolla V, Criniti V, Indaco S, Bordello A and Zappia V: p21Cip1 gene expression is modulated by Egr1: a novel regulatory mechanism involved in the resveratrol antiproliferative effect. J Biol Chem 278: 23360-23368, 2003.
216. Delia Ragione F, Cucciolla V, Criniti V, Indaco S, Borriello A and Zappia V: Antioxidants induce different phenotypes by a distinct modulation of signal transduction. FEBS Lett 552: 289-294, 2002.
217. El-Mowafy AM and White RE: Resveratrol inhibits MAPK activity and nuclear translocation in coronary artery smooth muscle: reversal of endothelin-1 stimulatory effects. FEBS Lett 451: 63-67, 1999.
218. Woo JH, Lim JH, Kim YH, Suh SI, Min DS, Chang JS, Lee YH, Park JW and Kwon TK: Resveratrol inhibits phorbol myristate acetate-induced matrix metalloproteinase-9 expression by inhibiting JNK and PKC delta signal transduction. Oncogene, 2003.
219. Garcia-Garcia J, Micol V, de Godos A and Gomez-Fernandez JC: The cancer chemopreventive agent resveratrol is incorporated into model membranes, and inhibits protein kinase C alpha activity. Arch Biochem Biophys 572: 382-388, 1999.
220. Haworth RS and Avkiran M: Inhibition of protein kinase D by resveratrol. Biochem Pharmacol 62: 1647-1651, 2001.
221. Uhle S, Medalia O, Waldron R, Dumdey R, Henklein P, Bech-Otschir D, Huang X, Berse M, Sperling J, Schade R and Dubiel W: Protein kinase CK2 and protein kinase D are associated with the COP9 signalosome. Embo J 22: 1302-1312, 2003.
222. Chung EY, Kim BH, Lee MK, Yun YP, Lee SH, Min KR and Kim Y: Anti-inflammatory effect of the oligomeric stilbene alpha-Viniferin and its mode of the action through inhibition of cyclooxygenase-2 and inducible nitric oxide synthase. Planta Med 69: 710-714, 2003.
223. Palmieri L, Mameli M and Ronca G: Effect of resveratrol and some other natural compounds on tyrosine kinase activity and on cytolysis. Drugs Exp Clin Res 25: 79-85, 1999.
224. Oliver JM, Burg DL, Wilson BS, McLaughlin JL and Geahlen RL: Inhibition of mast cell Fc epsilon R1-mediated signaling and effector function by the Syk-selective inhibitor, piceatannol. J Biol Chem 269: 29697-29703, 1994.
225. Takada Y, Mukhopadhyay A, Kundu GC, Mahabeleshwar GH, Singh S and Aggarwal BB: Hydrogen peroxide activates NF-kappa B through tyrosine phosphorylation of I kappa B alpha and serine phosphorylation of p65: evidence for the involvement of I kappa B alpha kinase and Syk protein-tyrosine kinase. J Biol Chem 278: 24233-24241, 2003.
226. She QB, Ma WY, Wang M, Kaji A, Ho CT and Dong Z: Inhibition of cell transformation by resveratrol and its derivatives: differential effects and mechanisms involved. Oncogene 22: 2143-2150, 2003.
227. MacCarrone M, Lorenzon T, Guerrieri P and Agro AF: Resveratrol prevents apoptosis in K562 cells by inhibiting lipoxygenase and cyclooxygenase activity. Eur J Biochem 265: 27-34, 1999.
228. Mutoh M, Takahashi M, Fukuda K, Matsushima-Hibiya Y, Mutoh H, Sugimura T and Wakabayashi K: Suppression of cyclooxygenase-2 promoter-dependent transcriptional activity in colon cancer cells by chemopreventive agents with a resorcin-type structure. Carcinogenesis 21: 959-963, 2000.
229. Yu L, Sun ZJ, Wu SL and Pan CE: Effect of resveratrol on cell cycle proteins in murine transplantable liver cancer. World J Gastroenterol 9: 2341-2343, 2003.
230. Ferrero ME, Bertelli AA, Pellegatta F, Fulgenzi A, Corsi MM, and Bertelli A: Phytoalexin resveratrol (3-4′-5-trihydroxystilbene) modulates granulocyte and monocyte endothelial adhesion. Transplant Proc 30: 4191-4193, 1998.
231. Ferrero ME, Bertelli AE, Fulgenzi A, Pellegatta F, Corsi MM, Bonfrate M, Ferrara F, De Caterina R, Giovannini L and Bertelli A: Activity in vitro of resveratrol on granulocyte and monocyte adhesion to endothelium. Am J Clin Nutr 68: 1208-1214, 1998.
232. Wang MJ, Huang HM, Hsieh SJ, Jeng KC and Kuo JS: Resveratrol inhibits interleukin-6 production in cortical mixed glial cells under hypoxia/hypoglycemia followed by reoxygenation. J Neuroimmunol 112: 28-34, 2001.
233. Zhong M, Cheng GF, Wang WJ, Guo Y, Zhu XY and Zhang JT: Inhibitory effect of resveratrol on interleukin 6 release by stimulated peritoneal macrophages of mice. Phytomedicine 6: 79-84, 1999.
234. Wadsworth TL and Koop DR: Effects of the wine polyphenolics quercetin and resveratrol on pro-inflammatory cytokine expression in RAW 264.7 macrophages. Biochem Pharmacol 57: 941-949, 1999.
235. Culpitt SV, Rogers DF, Fenwick PS, Shah P, De Matos C, Russell RE, Barnes PJ and Donnelly LE: Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD. Thorax 58: 942-946, 2003.
236. Boscolo P, del Signore A, Sabbioni E, Di Gioacchino M, Di Giampaolo L, Reale M, Conti P, Paganelli R and Giaccio M: Effects of resveratrol on lymphocyte proliferation and cytokine release. Ann Clin Lab Sci 33: 226-231, 2003.
237. Szende B, Tyihak E and Kiraly-Veghely Z: Dose-dependent effect of resveratrol on proliferation and apoptosis in endothelial and tumor cell cultures. Exp Mol Med 32: 88-92, 2000.
238. Igura K, Ohta T, Kuroda Y and Kaji K: Resveratrol and quercetin inhibit angiogenesis in vitro. Cancer Lett 171: 11-16, 2001.
239. Bruder JL, Hsieh T, Lerea KM, Olson SC and Wu JM: Induced cytoskeletal changes in bovine pulmonary artery endothelial cells by resveratrol and the accompanying modified responses to arterial shear stress. BMC Cell Biol 2: 1, 2001.
240. Lin MT, Yen ML, Lin CY and Kuo ML: Inhibition of vascular endothelial growth factor-induced angiogenesis by resveratrol through interruption of Src-dependent vascular endothelial cadherin tyrosine phosphorylation. Mol Pharmacol 64: 1029-1036, 2003.
241. Abou-Agag LH, Aikens ML, Tabengwa EM, Benza RL, Shows SR, Grenett HE and Booyse FM: Polyphyenolics increase t-PA and u-PA gene transcription in cultured human endothelial cells. Alcohol Clin Exp Res 25: 155-162, 2001.
242. Bertelli AA, Ferrara F, Diana G, Fulgenzi A, Corsi M, Ponti W, Ferrero ME and Bertelli A: Resveratrol, a natural stilbene in grapes and wine, enhances intraphagocytosis in human promonocytes: a co-factor in antiinflammatory and anticancer chemopreventive activity. Int J Tissue React 21: 93-104, 1999.
243. Li HF, Chen SA and Wu SN: Evidence for the stimulatory effect of resveratrol on Ca(2+)-activated K+ current in vascular endothelial cells. Cardiovasc Res 45: 1035-1045, 2000.
244. Fulgenzi A, Bertelli AA, Magni E, Ferrero E and Ferrero ME: In vivo inhibition of TNFalpha-induced vascular permeability by resveratrol. Transplant Proc 33: 2341-2343, 2001.
245. Brakenhielm E, Cao R and Cao Y: Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes. Faseb J 15: 1798-1800, 2001.
246. Khanna S, Roy S, Bagchi D, Bagchi M and Sen CK: Upregulation of oxidant-induced VEGF expression in cultured keratinocytes by a grape seed proanthocyanidin extract. Free Radic Biol Med 31: 38-42, 2001.
247. Ulsperger E, Hamilton G, Raderer M, Baumgartner G, Hejna M, Hoffmann O and Mallinger R: Resveratrol pretreatment desensitizes AHTO-7 human osteoblasts to growth stimulation in response to carcinoma cell supernatants. Int J Oncol 75: 955-959, 1999.
248. Piver B, Berthou F, Dreano Y and Lucas D: Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components. Toxicol Lett 125: 83-91, 2001.
249. Ciolino HP, Daschner PJ and Yeh GC: Resveratrol inhibits transcription of CYP1A1 in vitro by preventing activation of the aryl hydrocarbon receptor. Cancer Res 58: 5707-5712, 1998.
250. Chang TK, Chen J and Lee WB: Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2. J Pharmacol Exp Ther 299: 874-882, 2001.
251. Chan WK and Delucchi AB: Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4. Life Sci 67: 3103-3112, 2000.
252. Chang TK and Yeung RK: Effect of trans-resveratrol on 7-benzyloxy-4-trifluoromethylcoumarin O-dealkylation catalyzed by human recombinant CYP3A4 and CYP3A5. Can J Physiol Pharmacol 79: 220-226, 2001.
253. Chang TK, Lee WB and Ko HH: Trans-resveratrol modulates the catalytic activity and mRNA expression of the procarcinogen-activating human cytochrome P450 1B1. Can J Physiol Pharmacol 78: 874-881, 2000.
254. Potter GA, Patterson LH, Wanogho E, Perry PJ, Butler PC, Ijaz T, Ruparelia KC, Lamb JH, Farmer PB, Stanley LA and Burke MD: The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br J Cancer 86: 774-778, 2002.
255. Peter Guengerich F, Chun YJ, Kim D, Gillam EM and Shimada T: Cytochrome P450 1B1: a target for inhibition in anticarcinogenesis strategies. Mutat Res 523-524: 173-182, 2003.
256. Dubuisson JG, Dyess DL and Gaubatz JW: Resveratrol modulates human mammary epithelial cell O-acetyltransferase, sulfotransferase, and kinase activation of the heterocyclic amine carcinogen N-hydroxy-PhIP. Cancer Lett 182: 27-32, 2002.
257. Teel RW and Huynh H: Modulation by phytochemicals of cytochrome P450-linked enzyme activity. Cancer Lett 133: 135-141, 1998.
258. Ciolino HP and Yeh GC: The effects of resveratrol on CYP1A1 expression and aryl hydrocarbon receptor function in vitro. Adv Exp Med Biol 492: 183-193, 2001.
259. Kimura Y, Okuda H and Kubo M: Effects of stilbenes isolated from medicinal plants on arachidonate metabolism and degranulation in human polymorphonuclear leukocytes. J Ethnopharmacol 45: 131-139, 1995.
260. Kimura Y, Okuda H and Arichi S: Effects of stilbenes on arachidonate metabolism in leukocytes. Biochim Biophys Acta 834: 275-278, 1985.
261. Huang KS, Lin M and Cheng GF: Anti-inflammatory tetramers of resveratrol from the roots of Vitis amurensis and the conformations of the seven-membered ring in some oligostilbenes. Phytochemistry 58: 357-362, 2001.
262. Jang DS, Kang BS, Ryu SY, Chang IM, Min KR and Kim Y: Inhibitory effects of resveratrol analogs on unopsonized zyraosan-induced oxygen radical production. Biochem Pharmacol 57: 705-712, 1999.
263. Burkitt MJ and Duncan J: Effects of trans-resveratrol on copper-dependent hydroxyl-radical formation and DNA damage: evidence for hydroxyl-radical scavenging and a novel, glutathione-sparing mechanism of action. Arch Biochem Biophys 381: 253-263, 2000.
264. Miura T, Muraoka S, Ikeda N, Watanabe M and Fujimoto Y: Antioxidative and prooxidative action of stilbene derivatives. Pharmacol Toxicol 86: 203-208, 2000.
265. Tadolini B, Juliano C, Piu L, Franconi F and Cabrini L: Resveratrol inhibition of lipid peroxidation. Free Rad Res 33: 105-114, 2000.
266. Wang M, Jin Y and Ho CT: Evaluation of resveratrol derivatives as potential antioxidants and identification of a reaction product of resveratrol and 2, 2-diphenyl-1-picryhydrazyl radical. J Agric Food Chem 47: 3974-3977, 1999.
267. Murcia MA and Martinez-Tome M: Antioxidant activity of resveratrol compared with common food additives. J Food Prot 64: 379-384, 2001.
268. Olas B, Wachowicz B, Saluk-Juszczak J, Zielinski T, Kaca W and Buczynski A: Antioxidant activity of resveratrol in endotoxin-stimulated blood platelets. Cell Biol Toxicol 17: 117-125, 2001.
269. Stojanovic S, Sprinz H and Brede O: Efficiency and mechanism of the antioxidant action of trans-resveratrol and its analogues in the radical liposome oxidation. Arch Biochem Biophys 391: 79-89, 2001.
270. Belguendouz L, Fremont L and Linard A: Resveratrol inhibits metal ion-dependent and independent peroxidation of porcine low-density lipoproteins. Biochem Pharmacol 53: 1347-1355, 1997.
271. Martinez J and Moreno JJ: Effect of resveratrol, a natural polyphenolic compound, on reactive oxygen species and prostaglandin production. Biochem Pharmacol 59: 865-870, 2000.
272. Miller NJ and Rice-Evans CA: Antioxidant activity of resveratrol in red wine. Clin Chem 41: 1789, 1995.
273. Goldberg DM: More on antioxidant activity of resveratrol in red wine. Clin Chem 42: 113-114, 1996.
274. Amorini AM, Fazzina G, Lazzarino G, Tavazzi B, Di Pierro D, Santucci R, Sinibaldi F, Galvano F and Galvano G: Activity and mechanism of the antioxidant properties of cyanidin-3-O-beta-glucopyranoside. Free Rad Res 35: 953-966, 2001.
275. Win W, Cao Z, Peng X, Trush MA and Li Y: Different effects of genistein and resveratrol on oxidative DNA damage in vitro. Mutat Res 513: 113-120, 2002.
276. Frankel EN, Waterhouse AL and Kinsella JE: Inhibition of human LDL oxidation by resveratrol. Lancet 341: 1103-1104, 1993.
277. Rodrigue CM, Arous N, Bachir D, Smith-Ravin J, Romeo PH, Galacteros F and Garel MC: Resveratrol, a natural dietary phytoalexin, possesses similar properties to hydroxyurea towards erythroid differentiation. Br J Haematol 113: 500-507, 2001.
278. Mizutani K, Ikeda K, Kawai Y and Yamori Y: Resveratrol stimulates the proliferation and differentiation of osteoblastic MC3T3-E1 cells. Biochem Biophys Res Commun 253: 859-863, 1998.
279. Wang Q, Li H, Wang XW, Wu DC, Chen XY and Liu J: Resveratrol promotes differentiation and induces Fas-independent apoptosis of human medulloblastoma cells. Neurosci Lett 351: 83-86, 2003.
280. Gehm BD, McAndrews JM, Chien PY and Jameson JL: Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci USA 94: 14138-14143,1997.
281. Turner RT, Evans GL, Zhang M, Maran A and Sibonga JD: Is resveratrol an estrogen agonist in growing rats? Endocrinology 140: 50-54, 1999.
282. Basly JP, Marre-Fournier F, Le Bail JC, Habrioux G and Chulia AJ: Estrogenic/antiestrogenic and scavenging properties of (E)- and (Z)-resveratrol. Life Sci 66: 769-777, 2000.
283. Bowers JL, Tyulmenkov VV, Jernigan SC and Klinge CM: Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology 141: 3657-3667, 2000.
284. Stahl S, Chun TY and Gray WG: Phytoestrogens act as estrogen agonists in an estrogen-responsive pituitary cell line. Toxicol Appl Pharmacol 152: 41-48, 1998.
285. Culig Z, Klocker H, Bartsch G and Hobisch A: Androgen receptors in prostate cancer. Endocr Relat Cancer 9: 155-170, 2002.
286. Bertelli AA, Baccalini R, Battaglia E, Falchi M and Ferrero ME; Resveratrol inhibits TNF alpha-induced endothelial cell activation. Therapie 56: 613-616, 2001.
287. Ciolino HP and Yeh GC: Inhibition of aryl hydrocarbon-induced cytochrome P-450 1A1 enzyme activity and CYP1A1 expression by resveratrol. Mol Pharmacol 56: 760-767, 1999.
288. Yu C, Shin YG, Kosmeder JW, Pezzuto JM and van Breemen RB: Liquid chromatography/tandem mass spectrometric determination of inhibition of human cytochrome P450 isozymes by resveratrol and resveratrol-3-sulfate. Rapid Commun Mass Spectrom 17: 307-313, 2003.
289. Pozo-Guisado E, Lorenzo-Benayas MJ and Fernandez-Salguero PM: Resveratrol modulates the phosphoinositide 3-kinase pathway through an estrogen receptor alpha-dependent mechanism: relevance in cell proliferation. Int J Cancer 109: 167-173, 2004.
290. Holian O and Walter RJ: Resveratrol inhibits the proliferation of normal human keratinocytes in vitro. J Cell Biochem Suppl 36: 55-62, 2001.
291. Mnjoyan ZH and Fujise K: Profound negative regulatory effects by resveratrol on vascular smooth muscle cells: a role of p53-p21(WAF1/CIP1) pathway. Biochem Biophys Res Commun 311: 546-552, 2003.
292. Cavallaro A, Ainis T, Bottari C and Fimiani V: Effect of resveratrol on some activities of isolated and in whole blood human neutrophils. Physiol Res 52: 555-562, 2003.
293. Losa GA: Resveratrol modulates apoptosis and oxidation in human blood mononuclear cells. Eur J Clin Invest 33: 818-823, 2003.
294. Sgambato A, Ardito R, Faraglia B, Boninsegna A, Wolf FI and Cittadini A: Resveratrol, a natural phenolic compound, inhibits cell proliferation and prevents oxidative DNA damage. Mutat Res 496: 171-180, 2001.
295. Uenobe F, Nakamura S and Miyazawa M: Antimutagenic effect of resveratrol against Trp-P-1. Mutat Res 373: 197-200, 1997.
296. Revel A, Raanani H, Younglai E, Xu J, Han R, Savouret JF and Casper RF: Resveratrol, a natural aryl hydrocarbon receptor antagonist, protects sperm from DNA damage and apoptosis caused by benzo(a)pyrene. Reprod Toxicol 75: 479-486, 2001.
297. Ahmad A, Farhan Asad S, Singh S and Hadi SM: DNA breakage by resveratrol and Cu(II): reaction mechanism and bacteriophage inactivation. Cancer Lett 154: 29-37, 2000.
298. Fukuhara K and Miyata N: Resveratrol as a new type of DNA-cleaving agent. Bioorg Med Chem Lett 8: 3187-3192, 1998.
299. Chen X, Shen B, Xia L, Khaletzkiy A, Chu D, Wong JY and Li JJ: Activation of nuclear factor kappaB in radioresistance of TP53-inactive human keratinocytes. Cancer Res 62: 1213-1221, 2002.
300. Terakado N, Shintani S, Yano J, Chunnan L, Mihara M, Nakashiro K and Hamakawa H: Overexpression of cyclooxygenase-2 is associated with radioresistance in oral squamous cell carcinoma. Oral Oncol 40: 383-389, 2004.
301. Russo SM, Tepper JE, Baldwin AS Jr, Liu R, Adams J, Elliott P and Cusack JC Jr: Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys 50: 183-193, 2001.
302. Pyo H, Choy H, Amorino GP, Kim JS, Cao Q, Hercules SK and DuBois RN: A selective cyclooxygenase-2 inhibitor, NS-398, enhances the effect of radiation in vitro and in vivo preferentially on the cells that express cyclooxygenase-2. Clin Cancer Res 7: 2998-3005, 2001.
303. Borisova IG and Budnitskaia EV: In vitro radiation sensitivity of lipoxygenase systems. Radiobiologiia 21: 58-62, 1981.
304. Kubota T, Uemura Y, Kobayashi M and Taguchi H: Combined effects of resveratrol and paclitaxel on lung cancer cells. Anticancer Res 23: 4039-4046, 2003.
305. Fulda S and Debatin KM: Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res 64: 337-346, 2004.
306. Jazirehi AR and Bonavida B: Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther 3: 71-84, 2004.
307. Ahmad KA, Clement MV, Hanif IM and Pervaiz S: Resveratrol inhibits drug-induced apoptosis in human leukemia cells by creating an intracellular milieu nonpermissive for death execution. Cancer Res 64: 1452-1459, 2004.
308. Chun YJ, Kim MY and Guengerich FP: Resveratrol is a selective human cytochrome P450 1A1 inhibitor. Biochem Biophys Res Commun 262: 20-24, 1999.
309. Belguendouz L, Fremont L and Gozzelino MT: Interaction of transresveratrol with plasma lipoproteins. Biochem Pharmacol 55: 811-816, 1998.
310. Miura T, Muraoka S and Fujimoto Y: Inactivation of creatine kinase induced by stilbene derivatives. Pharmacol Toxicol 90: 66-72, 2002.
311. Kitson TM, Kitson KE and Moore SA: Interaction of sheep liver cytosolic aldehyde dehydrogenase with quercetin, resveratrol and diethylstilbestrol. Chem Biol Interact 130-132: 57-69, 2001.
312. Zhou CX, Kong LD, Ye WC, Cheng CH and Tan RX: Inhibition of xanthine and monoamine oxidases by stilbenoids from Veratrum taliense. Planta Med 67: 158-161, 2001.
313. Fontecave M, Lepoivre M, Elleingand E, Gerez C and Guittet O: Resveratrol, a remarkable inhibitor of ribonucleotide reductase. FEBS Lett 421: 277-279, 1998.
314. Falchetti R, Fuggetta MP, Lanzilli G, Tricarico M and Ravagnan G: Effects of resveratrol on human immune cell function. Life Sci 70: 81-96, 2001.
315. Gao X, Deeb D, Media J, Divine G, Jiang H, Chapman RA and Gautam SC: Immunomodulatory activity of resveratrol: discrepant in vitro and in vivo immunological effects. Biochem Pharmacol 66: 2427-2435, 2003.
316. Rotondo S, Rajtar G, Manarini S, Celardo A, Rotillo D, de Gaetano G, Evangelista V and Cerletti C: Effect of trans-resveratrol, a natural polyphenolic compound, on human polymorphonuclear leukocyte function. Br J Pharmacol 123: 1691-1699, 1998.
317. Fustier P, Le Corre L, Chalabi N, Vissac-Sabatier C, Communal Y, Bignon YJ and Bernard-Gallon DJ: Resveratrol increases BRCA1 and BRCA2 mRNA expression in breast tumour cell lines. Br J Cancer 89: 168-172, 2003.
318. Bertelli AA, Giovannini L, Stradi R, Urien S, Tillement JP and Bertelli A: Evaluation of kinetic parameters of natural phytoalexin in resveratrol orally administered in wine to rats. Drugs Exp Clin Res 24: 51-55, 1998.
319. Andlauer W, Kolb J, Siebert K and Furst P: Assessment of resveratrol bioavailability in the perfused small intestine of the rat. Drugs Exp Clin Res 26: 47-55, 2000.
320. Kuhnle G, Spencer JP, Chowrimootoo G, Schroeter H, Debnam ES, Srai SK, Rice-Evans C and Hahn U: Resveratrol is absorbed in the small intestine as resveratrol glucuronide. Biochem Biophys Res Commun 272: 212-217, 2000.
321. de Sand C, Pietrabissa A, Mosca F and Pacifici GM: Glucuronidation of resveratrol, a natural product present in grape and wine, in the human liver. Xenobiotica 30: 1047-1054, 2000.
322. Aumont V, Krisa S, Battaglia E, Netter P, Richard T, Merillon JM, Magdalou J and Sabolovic N: Regioselective and stereospecific glucuronidation of trans- and cis-resveratrol in human. Arch Biochem Biophys 393: 281-289, 2001.
323. De Santi C, Pietrabissa A, Spisni R, Mosca F and Pacifici GM: Sulphation of resveratrol, a natural product present in grapes and wine, in the human liver and duodenum. Xenobiotica 30: 609-617, 2000.
324. Bertelli AA, Giovannini L, Stradi R, Urien S, Tillement JP and Bertelli A: Kinetics of trans- and cis-resveratrol (3,4′,5-trihydroxystilbene) after red wine oral administration in rats. Int J Clin Pharmacol Res 16: 77-81, 1996.
325. Bertelli A, Bertelli AA, Gozzini A and Giovannini L: Plasma and tissue resveratrol concentrations and pharmacological activity. Drugs Exp Clin Res 24: 133-138, 1998.
326. Corsi MM, Ponti W, Ferrara F, Venditti A, Malavazos A, Ruscica M, Mihali D, Diana GM, Paraboni L and Bertelli AA: Nanomolar level of resveratrol (trans-3,5,4′-trihydroxystilbene) is required, but is not sufficient, to inhibit the growth of human monocytoid tumor cells through an apoptotic-like mechanism. Drugs Exp Clin Res 28: 235-242, 2002.
327. Kaldas MI, Walle UK and Walle T: Resveratrol transport and metabolism by human intestinal Caco-2 cells. J Pharm Pharmacol 55: 307-312, 2003.
328. Yu C, Shin YG, Chow A, Li Y, Kosmeder JW, Lee YS, Hirschelman WH, Pezzuto JM, Mehta RG and van Breemen RB: Human, rat, and mouse metabolism of resveratrol. Pharm Res 19: 1907-1914, 2002.
329. Sale S, Verschoyle RD, Boocock D, Jones DJ, Wilsher N, Ruparelia KC, Potter GA, Farmer PB, Steward WP and Gescher AJ: Pharmacokinetics in mice and growth-inhibitory properties of the putative cancer chemopreventive agent resveratrol and the synthetic analogue trans 3,4,5,4′- tetramethoxystilbene. Br J Cancer 90: 736-744, 2004.
330. Vitrac X, Desmouliere A, Brouillaud B, Krisa S, Deffieux G, Barthe N, Rosenbaum J and Merillon JM: Distribution of [14C]-trans-resveratrol, a cancer chemopreventive polyphenol, in mouse tissues after oral administration. Life Sci 72: 2219-2233, 2003.
331. Meng X, Maliakal P, Lu H, Lee MJ and Yang CS: Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice. J Agric Food Chem 52: 935-942, 2004.
332. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC and Pezzuto JM: Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218-220, 1997.
333. Jang M and Pezzuto JM: Effects of resveratrol on 12-O- tetradecanoylphorbol-13-acetate-induced oxidative events and gene expression in mouse skin. Cancer Lett 134: 81-89, 1998.
334. Kapadia GJ, Azuine MA, Tokuda H, Takasaki M, Mukainaka T, Konoshima T and Nishino H: Chemopreventive effect of resveratrol, sesamol, sesame oil and sunflower oil in the Epstein-Barr virus early antigen activation assay and the mouse skin two-stage carcinogenesis. Pharmacol Res 45: 499-505, 2002.
335. Soleas GJ, Grass L, Josephy PD, Goldberg DM and Diamandis EP: A comparison of the anticarcinogenic properties of four red wine polyphenols. Clin Biochem 35: 119-124, 2002.
336. Afaq F, Adhami VM, Ahmad N and Mukhtar H: Botanical antioxidants for chemoprevention of photocarcinogenesis. Front Biosci 7: d784-792, 2002.
337. Breinholt VM, Molck AM, Svendsen GW, Daneshvar B, Vinggaard AM, Poulsen M and Dragsted LO: Effects of dietary antioxidants and 2-amino-3-methylimidazo[4, 5-f]-quinoline (IQ) on preneoplastic lesions and on oxidative damage, hormonal
338. Banerjee S, Bueso-Ramos C and Aggarwal BB: Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res 62: 4945-4954, 2002.
339. Sato M, Pei RJ, Yuri T, Danbara N, Nakane Y and Tsubura A: Prepubertal resveratrol exposure accelerates N-methyl-N-nitrosourea-induced mammary carcinoma in female Sprague-Dawley rats. Cancer Lett 202: 137-145, 2003.
340. Hecht SS, Kenney PM, Wang M, Trushin N, Agarwal S, Rao AV and Upadhyaya P: Evaluation of butylated hydroxyanisole, myo-inositol, curcumin, esculetin, resveratrol and lycopene as inhibitors of benzo[a]pyrene plus 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis in A/J mice. Cancer Lett 137: 123-130, 1999.
341. Revel A, Raanani H, Younglai E, Xu J, Rogers I, Han R, Savouret JF and Casper RF: Resveratrol, a natural aryl hydrocarbon receptor antagonist, protects lung from DNA damage and apoptosis caused by benzo[a]pyrene. J Appl Toxicol 23: 255-261, 2003.
342. Li ZG, Hong T, Shimada Y, Komoto I, Kawabe A, Ding Y, Kaganoi J, Hashimoto Y and Imamura M: Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by resveratrol. Carcinogenesis 23: 1531-1536, 2002.
343. Liu, HS, Pan, CE, Yang, W, and Liu, XM Antitumor and immunomodulatory activity of resveratrol on experimentally implanted tumor of H22 in Balb/c mice. World J Gastroenterol, 9: 1474-1476, 2003.
344. Ignatowicz E, Balana B, Vulimiri SV, Szaefer H and Baer-Dubowska W: The effect of plant phenolics on the formation of 7,12-dimethylbenz[a]anthracene-DNA adducts and TPA-stimulated polymorphonuclear neutrophils chemiluminescence in vitro. Toxicology 189: 199-209, 2003.
345. Cadenas S and Barja G: Resveratrol, melatonin, vitamin E, and PBN protect against renal oxidative DNA damage induced by the kidney carcinogen KBrO3. Free Rad Biol Med 26: 1531-1537, 1999.
346. Ziegler CC, Rainwater L, Whelan J and McEntee MF: Dietary resveratrol does not affect intestinal tumorigenesis in apc(min/+) mice. J Nutr 134: 5-10, 2004.
347. Carbo N, Costelli P, Baccino FM, Lopez-Soriano FJ and Argiles JM: Resveratrol, a natural product present in wine, decreases tumour growth in a rat tumour model. Biochem Biophys Res Commun 254: 739-743, 1999.
348. Caltagirone S, Rossi C, Poggi A, Ranelletti FO, Natali PG, Brunetti M, Aiello FB and Piantelli M: Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential. Int J Cancer 87: 595-600, 2000.
349. Kimura Y and Okuda H: Resveratrol isolated from Polygonum cuspidatum root prevents tumor growth and metastasis to lung and tumor-induced neovascularization in Lewis lung carcinoma-bearing mice. J Nutr 131: 1844-1849, 2001.
350. Schneider Y, Duranton B, Gosse F, Schleiffer R, Seiler N and Raul F: Resveratrol inhibits intestinal tumorigenesis and modulates host-defense-related gene expression in an animal model of human familial adenomatous polyposis. Nutr Cancer 39: 102-107, 2001.
351. Kimura Y and Okuda H: Effects of naturally occurring stilbene glucosides from medicinal plants and wine, on tumour growth and lung metastasis in Lewis lung carcinoma-bearing mice. J Pharm Pharmacol 52: 1287-1295, 2000.
352. Mishima S, Matsumoto K, Futamura Y, Araki Y, Ito T, Tanaka T, Iinuma M, Nozawa Y and Akao Y: Antitumor effect of stilbenoids from Valeria indica against allografted sarcoma S-180 in animal model. J Exp Ther Oncol 3: 283-288, 2003.
353. Juan ME, Vinardell MP and Planas JM: The daily oral administration of high doses of trans-resveratrol to rats for 28 days is not harmful. J Nutr 132: 257-260, 2002.
354. Morales AI, Buitrago JM, Santiago JM, Fernandez-Tagarro M, Lopez-Novoa JM and Perez-Barriocanal F: Protective effect of trans-resveratrol on gentamicin-induced nephrotoxicity. Antioxid Redox Signal 4: 893-898, 2002.
355. Gautam SC, Xu YX, Dumaguin M, Janakiraman N and Chapman RA: Resveratrol selectively inhibits leukemia cells: a prospective agent for ex vivo bone marrow purging. Bone Marrow Transplant 25: 639-645, 2000.
356. Goldberg DM, Yan J and Soleas GJ: Absorption of three wine-related polyphenols in three different matrices by healthy subjects. Clin Biochem 36: 79-87, 2003.
357. Pace-Asciak CR, Rounova O, Hahn SE, Diamandis EP and Goldberg DM: Wines and grape juices as modulators of platelet aggregation in healthy human subjects. Clin Chim Acta 246: 163-182, 1996.
358. Wang Z, Zou J, Huang Y, Cao K, Xu Y and Wu JM: Effect of resveratrol on platelet aggregation in vivo and in vitro. Chin Med J (Engl) 115: 378-380, 2002.
359. Blardi P, De Lalla A, Volpi L and Di Perri T: Stimulation of endogenous adenosine release by oral administration of quercetin and resveratrol in man. Drugs Exp Clin Res 25: 105-110, 1999.
360. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL, Scherer B and Sinclair DA: Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 425: 191-196, 2003.
361. Soleas GJ, Angelini M, Grass L, Diamandis EP and Goldberg DM Absorption of trans-resveratrol in rats. Methods Enzymol 335: 145-154, 2001.
362. Henry LA and Witt DM: Resveratrol: phytoestrogen effects on reproductive physiology and behavior in female rats. Horm Behav 41: 220-228, 2002.
363. Gupta YK, Chaudhary G, Sinha K and Srivastava AK: Protective effect of resveratrol against intracortical FeCB-induced model of posttraumatic seizures in rats. Methods Find Exp Clin Pharmacol 23: 241-244, 2001.
364. Sharma M and Gupta YK: Chronic treatment with trans resveratrol prevents intracerebroventricular streptozotocin induced cognitive impairment and oxidative stress in rats. Life Sci 71: 2489-2498, 2002.
365. Gentilli M, Mazoit JX, Bouaziz H, Fletcher D, Casper RF, Benhamou D and Savouret JF: Resveratrol decreases hyperalgesia induced by carrageenan in the rat hind paw. Life Sci 68: 1317-1321, 2001.
366. Kubo K, Aral O, Omura M, Watanabe R, Ogata R and Aou S: Low dose effects of bisphenol A on sexual differentiation of the brain and behavior in rats. Neurosci Res 45: 345-356, 2003.
367. Feng YH, Zhou WL, Wu QL, Li XY, Zhao WM and Zou JP: Low dose of resveratrol enhanced immune response of mice. Acta Pharmacol Sin 23: 893-897, 2002.
368. Afaq F, Adhami VM and Ahmad N: Prevention of short-term ultraviolet B radiation-mediated damages by resveratrol in SKH-1 hairless mice. Toxicol Appl Pharmacol 186: 28-37, 2003.
369. Wang Q, Xu J, Rottinghaus GE, Simonyi A, Lubahn D, Sun GY and Sun AY: Resveratrol protects against global cerebral ischemic injury in gerbils. Brain Res 958: 439-447, 2002.
370. Zou JG, Wang ZR, Huang YZ, Cao KJ and Wu JM: Effect of red wine and wine polyphenol resveratrol on endothelial function in hypercholesterolemic rabbits. Int J Mol Med 11: 317-320, 2003.